对于肛周克罗恩病患者，从静脉注射到皮下注射英夫利昔单抗是安全可行的。

IF 3.9 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Therapeutic Advances in Gastroenterology Pub Date : 2025-03-22 eCollection Date: 2025-01-01 DOI:10.1177/17562848251326471

Pauline Wils, Mathurin Fumery, Maria Nachury, Clara Yzet, Dilek Coban, Anthony Buisson

{"title":"对于肛周克罗恩病患者，从静脉注射到皮下注射英夫利昔单抗是安全可行的。","authors":"Pauline Wils, Mathurin Fumery, Maria Nachury, Clara Yzet, Dilek Coban, Anthony Buisson","doi":"10.1177/17562848251326471","DOIUrl":null,"url":null,"abstract":"Background and objectives: We assessed the evolution of perianal lesions after switching intravenous (IV) to subcutaneous (SC) infliximab in patients with Crohn's disease (CD).Design: Subgroup analysis of REMSWITCH studies.Methods: We described the clinical and MRI outcomes of patients with a prior or current CD perianal lesions after the switch.Results: In REMSWITCH, 40 CD patients had a prior history of perianal lesions. No patient experienced a new perianal lesion (median follow-up = 18 months). Among the three patients (3/40, 7.5%) with clinically active perianal lesions at baseline, two patients had no more perianal lesions at month 18 while the last patient experienced lesions worsening. Another one with active perianal lesions on MRI but no symptom at baseline did not have any relapse within 18 months. Only one patient (1/40, 2.5%) had a perianal relapse (at month 25) with remission recapture after SC infliximab intensification.Conclusion: Switching from IV to SC infliximab in CD with perianal lesions is safe and feasible.","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251326471"},"PeriodicalIF":3.9000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946279/pdf/","citationCount":"0","resultStr":"{\"title\":\"Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's disease.\",\"authors\":\"Pauline Wils, Mathurin Fumery, Maria Nachury, Clara Yzet, Dilek Coban, Anthony Buisson\",\"doi\":\"10.1177/17562848251326471\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and objectives: We assessed the evolution of perianal lesions after switching intravenous (IV) to subcutaneous (SC) infliximab in patients with Crohn's disease (CD).Design: Subgroup analysis of REMSWITCH studies.Methods: We described the clinical and MRI outcomes of patients with a prior or current CD perianal lesions after the switch.Results: In REMSWITCH, 40 CD patients had a prior history of perianal lesions. No patient experienced a new perianal lesion (median follow-up = 18 months). Among the three patients (3/40, 7.5%) with clinically active perianal lesions at baseline, two patients had no more perianal lesions at month 18 while the last patient experienced lesions worsening. Another one with active perianal lesions on MRI but no symptom at baseline did not have any relapse within 18 months. Only one patient (1/40, 2.5%) had a perianal relapse (at month 25) with remission recapture after SC infliximab intensification.Conclusion: Switching from IV to SC infliximab in CD with perianal lesions is safe and feasible.\",\"PeriodicalId\":48770,\"journal\":{\"name\":\"Therapeutic Advances in Gastroenterology\",\"volume\":\"18 \",\"pages\":\"17562848251326471\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946279/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562848251326471\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848251326471","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的：我们评估了克罗恩病（CD）患者将英夫利昔单抗静脉注射（IV）改为皮下注射（SC）后肛周病变的演变。设计：REMSWITCH研究的亚组分析。方法：我们描述了转换后既往或当前有CD肛周病变的患者的临床和MRI结果。结果：在REMSWITCH中，40例CD患者既往有肛周病变史。没有患者出现新的肛周病变（中位随访= 18个月）。基线时有临床活动性肛周病变的3例患者（3/40,7.5%）中，2例患者在18个月时不再有肛周病变，最后1例患者出现病变恶化。另一名在MRI上有活动性肛周病变但在基线时没有症状的患者在18个月内没有复发。只有1名患者（1/ 40,2.5%）在SC英夫利昔单抗强化后肛周复发（25个月）并缓解。结论：对于伴有肛周病变的CD患者，从静脉注射改为皮下注射英夫利昔单抗是安全可行的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's disease.

Background and objectives: We assessed the evolution of perianal lesions after switching intravenous (IV) to subcutaneous (SC) infliximab in patients with Crohn's disease (CD).

Design: Subgroup analysis of REMSWITCH studies.

Methods: We described the clinical and MRI outcomes of patients with a prior or current CD perianal lesions after the switch.

Results: In REMSWITCH, 40 CD patients had a prior history of perianal lesions. No patient experienced a new perianal lesion (median follow-up = 18 months). Among the three patients (3/40, 7.5%) with clinically active perianal lesions at baseline, two patients had no more perianal lesions at month 18 while the last patient experienced lesions worsening. Another one with active perianal lesions on MRI but no symptom at baseline did not have any relapse within 18 months. Only one patient (1/40, 2.5%) had a perianal relapse (at month 25) with remission recapture after SC infliximab intensification.

Conclusion: Switching from IV to SC infliximab in CD with perianal lesions is safe and feasible.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Therapeutic Advances in Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.70

自引率

2.40%

发文量

103

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.